Impact of ABCG2 Polymorphisms on the Clinical Outcome of TKIs Therapy in Chinese Advanced Non-Small-Cell Lung Cancer Patients

被引：0
|
作者：
Chen, Xueqin [1 ]
Chen, Dadong [1 ]
Yang, Shaoyu [1 ]
Pan, Yuelong [1 ]
Li, Xin [1 ]
Ma, Shenglin [1 ]
机构：
[1] Hangzhou First Peoples Hosp, Dept Med Oncol, Hangzhou, Zhejiang, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2015年 / 10卷 / 09期
关键词：
TKI; ABCG2; polymorphism; NSCLC; OS;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
MINI05.02
引用
收藏
页码：S277 / S277
页数：1
相关论文
共 50 条
  • [1] Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients
    Chen, Xueqin
    Chen, Dadong
    Yang, Shaoyu
    Ma, Ruobing
    Pan, Yuelong
    Li, Xin
    Ma, Shenglin
    CANCER CELL INTERNATIONAL, 2015, 15 : 1
  • [2] Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patients
    Xueqin Chen
    Dadong Chen
    Shaoyu Yang
    Ruobing Ma
    Yuelong Pan
    Xin Li
    Shenglin Ma
    Cancer Cell International, 15
  • [3] Impact of ABCG2 polymorphisms on the clinical outcome and toxicity of gefitinib in non-small-cell lung cancer patients
    Lemos, Clara
    Giovannetti, Elisa
    Zucali, Paolo A.
    Assaraf, Yehuda G.
    Scheffer, George L.
    van der Straaten, Tahar
    D'Incecco, Armida
    Falcone, Alfredo
    Guchelaar, Henk-Jan
    Danesi, Romano
    Santoro, Armando
    Giaccone, Giuseppe
    Tibaldi, Carmelo
    Peters, Godefridus J.
    PHARMACOGENOMICS, 2011, 12 (02) : 159 - 170
  • [4] Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non-small-cell lung cancer
    Akasaka, Keiichi
    Kaburagi, Takayuki
    Yasuda, Shin'ichi
    Ohmori, Kyoko
    Abe, Kaori
    Sagara, Hironori
    Ueda, Yoshihiko
    Nagao, Koshu
    Imura, Johji
    Imai, Yasuo
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010, 66 (04) : 691 - 698
  • [5] Impact of functional ABCG2 polymorphisms on the adverse effects of gefitinib in Japanese patients with non–small-cell lung cancer
    Keiichi Akasaka
    Takayuki Kaburagi
    Shin’ichi Yasuda
    Kyoko Ohmori
    Kaori Abe
    Hironori Sagara
    Yoshihiko Ueda
    Koshu Nagao
    Johji Imura
    Yasuo Imai
    Cancer Chemotherapy and Pharmacology, 2010, 66 : 691 - 698
  • [6] Associations of ABCB1, ABCC2, and ABCG2 polymorphisms with irinotecan-pharmacokinetics and clinical outcome in patients with advanced non-small cell lung cancer
    Han, Ji-Youn
    Lim, Hyeong-Seok
    Yoo, Yeon-Kyeong
    Shin, Eun Soon
    Park, Yong Hoon
    Lee, Sung Young
    Lee, Jong-Eun
    Lee, Dea Ho
    Kim, Heung Tae
    Lee, Jin Soo
    CANCER, 2007, 110 (01) : 138 - 147
  • [7] Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib
    Ma, Fei
    Sun, Tong
    Shi, Yuankai
    Yu, Dianke
    Tan, Wen
    Yang, Ming
    Wu, Chen
    Chu, Datong
    Sun, Yan
    Xu, Binghe
    Lin, Dongxin
    LUNG CANCER, 2009, 66 (01) : 114 - 119
  • [8] Association of polymorphisms at HORMAD2 and prognosis in advanced non-small-cell lung cancer patients
    Zhang, Kai
    Tang, Shaowen
    Cao, Songyu
    Hu, Lingmin
    Pan, Yun
    Ma, Hongxia
    Guo, Xuejiang
    Wu, Shuangshuang
    Shen, Hongbing
    Hu, Zhibin
    CANCER EPIDEMIOLOGY, 2014, 38 (04) : 414 - 418
  • [9] Associations between ABCG2 gene polymorphisms and gefitinib toxicity in non-small cell lung cancer: a meta-analysis
    Tang, Lina
    Zhang, Chunling
    He, Hairong
    Pan, Zhenyu
    Fan, Di
    He, Yinli
    You, Haisheng
    Li, Yuanjie
    ONCOTARGETS AND THERAPY, 2018, 11 : 665 - 675
  • [10] ABCG2 Gene Expression in Non-Small Cell Lung Cancer
    Jelen, Agnieszka
    Zebrowska-Nawrocka, Marta
    Lochowski, Mariusz
    Szmajda-Krygier, Dagmara
    Balcerczak, Ewa
    BIOMEDICINES, 2024, 12 (10)
12345